Table 1.
Demographic, clinical, and laboratory parameters of the kidney transplant recipients according to their COVID-19 status.
| COVID-19 (+) (n = 46) | COVID-19 (−) (n = 45) | p | |
|---|---|---|---|
| Age (years) | 46.5 (36.8–55.0) | 37.0 (32.0–55.0) | 0.194 |
| Male, n (%) | 32 (69.6) | 27 (60.0) | 0.231 |
| Etiology of CKD | |||
| Diabetes mellitus, n (%) | 5 (10.9) | 3 (6.7) | 0.599 |
| Glomerulonephritis, n (%) | 8 (17.4) | 11 (24.4) | |
| Others, n (%) | 33 (71.7) | 31 (68.9) | |
| Living donor, n (%) | 36 (78.3) | 35 (77.8) | 0.600 |
| Transplantation duration (months) | 108.0 (48.0–147.0) | 84.0 (24.0–132.0) | 0.378 |
| COVID-19 in a household member, n (%) | 29 (64.4) | 3 (6.8) | <0.001 |
| Comorbidities | |||
| Diabetes, n (%) | 13 (28.3) | 11 (24.4) | 0.431 |
| Hypertension, n (%) | 31 (67.4) | 26 (57.8) | 0.232 |
| BMI (kg/m2) | 27.4 ± 4.5 | 24.7 ± 4.2 | 0.004 |
| Serum creatinine (mg/dL) | 1.28 (1.01–1.53) | 1.23 (1.02–1.72) | 0.778 |
| e-GFR* (mL/min/1.73 m2) | 64.9 ± 24.1 | 64.6 ± 31.6 | 0.955 |
| Baseline immunosuppression | |||
| Steroids, n (%) | 46 (100.0) | 42 (93.3) | 0.117 |
| Calcineurin inhibitor, n (%) | 43 (93.5) | 43 (95.6) | 0.511 |
| Mycophenolic acid derivatives, n (%) | 41 (89.1) | 35 (77.8) | 0.119 |
| m-TOR inhibitors, n (%) | 4 (8.7) | 4 (8.9) | 0.631 |
| Azathioprine, n (%) | 3 (6.5) | 7 (15.6) | 0.149 |
Values are presented as mean ± SD or as median and IQR.
CKD: chronic kidney disease, BMI: body mass index, m-TOR inhibitors: mechanistic target of rapamycin inhibitors.
*
Calculated using the CKD-EPI formula.